The Future: DNA Identify Theft?

Advances made in DNA sequencing technology and genomic analysis has lowered the cost of sequencing a genome from millions of dollars a decade ago to less than $500 today. And, because of this, there are a growing number of companies that are willing to quickly and cheaply sequence and analyze your DNA. While this may be medically beneficial and appealing to some, it may not be for everyone. Moreover, and perhaps more importantly, who will control access to and insure the privacy of your genetic information if you choose to have your genome sequenced and analyzed. 

Alan McHughen, PhD, a molecular biologist and Professor of Botany and Plant Sciences at the University of California-Riverside, who has previously written about privacy and access to personal genomic data, wrote an article for BioJobBlog that explores the ramifications and possibility of DNA identity theft in the future. Also, he has written a book 'Pandora's Picnic Basket; The Potential and Hazards of Genetically Modified Foods' to refute the myths and explore the genuine risks of genetic modification technology

Genetic Privacy

By Alan McHughen

For just $399 (plus shipping and handling), the scientists at 23and me.com will scan your complete genome. The DNA analysis reports on 118 different medical and health dispositions, your maternal and paternal ethnic ancestry, and a curious bunch of genetic trivia concerning your persona (is your earwax sticky or flaky?). All you do is pay the money and spit into a collection tube; they extract your DNA from the spit and look for half a million single nucleotide polymorphisms (SNPs) scattered throughout your genome, including many in or near genes associated with particular traits. Other companies offer similar services. For example, Decodeme.com charges $985, but catalogs twice as many SNPs, and you collect your DNA with a cheek swab.

Alternatively, if you don’t need the complete genome scan but are curious about specific medical conditions or family lineage, you can get less expensive gene tests from an increasing number of companies willing to take your money and DNA sample in exchange for the genetic information their scientists reveal. If heart disease runs in your family, you may either relieve or exacerbate your anxieties by shelling out $200 to have a cardio scan for relevant genetic predispositions. Or, for as little as $99, a man can have his Y chromosome probed to confirm his place in the family patrilineage, and possibly connect to ancient and famous princes or pirates.

These genetic information services, with prices now well into recreational and hobby budget range, provide the most personal, private — and unchangeable— information possible about you. The sinister side of this fascinating field is all too often overlooked—it can reveal your most intimate genetic details to strangers and nosy neighbors. While the various testing labs assure confidentiality, there is little to no control over personal genetic information. In the US, anything you discard is salvageable by anyone else, and your trash can become another’s treasure if it carries blood, saliva, hair, semen or any other DNA-laden bodily secretions.

While we worry about identity theft, personal financial or other private information, our uniquely personal information is up for grabs. The Genetic Information Nondiscrimination Act (GINA) of 2008 offers some protection, but it is limited to employment and medical insurance issues. GINA does not protect your genetic information from being abused by life insurers. Or nosey neighbors. 

Genetic privacy raises a whole spectrum of social, ethical, legal and medical issues. Suppose your neighbor salvages your trash and has your DNA analyzed. This local gossip then shares the juicy news that you have a “higher than average predisposition” to, say, alcoholism. Soon, everyone in the community shuns you as a latent alcoholic, and you have no idea why. The community knows more about your genetic makeup than you do. And, because they don’t know how to interpret statistical language such as “a higher than average predisposition”, those conditions may easily be exaggerated into probabilities, if not certainties.

If people have a right to know their own genetic information, they have the obverse right to NOT know. People can choose to remain ignorant about their genetic makeup. Consider, for example, Huntington’s disease (HD). This death sentence is one of the few health conditions almost due to genetics, and the DNA assay has been available for years. Curiously, most people at risk, i.e., those with HD in their direct lineage, choose NOT to take the test; they prefer not to know until (or if) symptoms appear. What happens when the local busybody lets the cat out of the bag on HD? Word will get around and the at-risk person will inevitably find out, if only by the ‘different’ treatment by neighbors, thus obliterating the exercise of their right to remain ignorant. Whether the test result is positive or negative on HD is immaterial at this point, the rights will have been violated. The DNA test for HD is currently more elaborate than the simple SNP analysis, but because SNPs associated with HD are being reported, it’s only a matter of time before they come generally available.

Perhaps you’ve suspected the woman down the street had a child from an adulterous one night stand a few years ago, and the cuckold husband remains a doting, if clueless, dad. Now, with just $89 (including overnight FedEx delivery!) and a little misdemeanor creativity, well within the standard ethical bounds of busybodies, you can satisfy your suspicions with a surreptitious and discrete paternity test. And, to provoke some real excitement in your sleepy small town, show the results to the husband.

A few minutes of thought and discussion generates many other issues and examples of the precarious security of personal genetic information and identity, and the potentially dire consequences of genetic information getting out. Society is yet to discuss the privacy issues surrounding genetic identity as vigorously as we have with personal financial or medical records. It’s getting late. Do you know where your DNA is?

 

Social Media: DNA Videos Rock

While pharmaceutical and biotechnology companies have been reluctant to use social media, Bio-Rad, Applied BioSystems and other life sciences reagent and instrumentation companies have jumped on the YouTube video train with reckless abandon.

A quick perusal of the molecular biology-related videos on YouTube reveals several scintillating titles like “Do the Double Helix,” “DNA Replication Rap,” and my personal favorite from Bio-Rad, “The PCR Song” (see video below)

 

 

Until next time....

Good Luck and Good Watching !!!! 

SocialTwist Tell-a-Friend

 

Update: Chinese Researchers Finish Sequencing the Giant Panda Genome

China's Beijing Genomics Institute in Shenzhen announced that it has mapped the entire genetic code for the giant panda using DNA sequencing and analysis equipment from San Diego-based Illumina. The project began in mid 2008 and was completed by Jan.2009.

The panda at the center of this discovery is Jingjing, who lives in China's Chengdu Panda Breeding Research Center and was the mascot for the 2008 Beijing Olympics. The genetic information from Jingjing is expected to be complemented in the future with genetic information from other pandas.

Scientists hope to use the data from the sequencing project to better understand panda biology and reproduction. Giant pandas are difficult to breed in captivity and are currently on the endangered species list.

In China, the panda's genome sequencing was ranked by the Chinese government as one of the top 10 technology achievements of the year, right up there with the nation's space shuttle and the completion of the Tibetan railway.

Until next time...

Good Luck and Good Job Hunting!!!!!!!

 

SocialTwist Tell-a-Friend

Did You Know?

In his book, “Free: The Future of a Radical Price” Chris Anderson, editor of Wired Magazine, asserts that the cost of DNA sequencing falls 50% each year. To that end, in February, a company called Complete Genomics based in Mountain View, California, announced it will read entire human genomes at $5000 a shot, starting in June this year. This will cost less than one-tenth of what companies charge today for genome sequencing. 

If you believe Anderson, in five years sequencing a human genome will be under $100. Based on these calculations, the window of opportunity for companies that sequence genomic DNA to make a profit is closing rapidly. So, if you were considering getting into the DNA sequencing biz, the right time may be now—before it is no longer a profitable biz model.

Until next time...


Good Luck and Good Sequencing!!!!!!!!!!!
 

SocialTwist Tell-a-Friend

 

A Big MOOve--The Cow Genome is Sequenced

The long sought after cow genome has been sequenced. Heralded as a milestone in animal genetics, unraveling the cow genome will provide scientists with “tantalizing clues to explain the essence of bovinity.” Two papers describing the results of the project will appear in today's issue of the journal Science. 

The cow who donated its DNA for sequencing was a Hereford named LI Dominette 01449 and is one of the estimated 94 million bovines in the US. The project, led by researchers at National Institutes of Health and the U.S. Department of Agriculture, was a gargantuan effort that spanned six years and involved more than 300 scientists from 25 countries and cost only $53 million. Based on sequence analyses, cows haver 22,000 genes as compared with 20,000 to 25,000 for humans. Some of the other findings include: 

  • Cattle and humans have about 80 percent of their genes in common

  • The organization of human chromosomes is closer to that of domestic cattle than to those of rats or mice, which are often used in lab tests of drugs intended for people.

  • Cattle chromosomes, like those of humans and other mammals, contain segmental duplications, which are large, almost identical copies of DNA present in at least two locations in a genome.

  • In domestic cattle, there are duplications related to immunity, metabolism, digestion, reproduction and lactation. Such duplications in humans have been related to a variety of disorders.

Researchers hope that elucidating the bovine genome will help them find ways to improve milk and meat production, develop new strategies to treat and prevent diseases and to reduce the carbon foot print of cows that release large amounts of greenhouse gases that contribute to global warming.

Great news to receive on National DNA Day! 

Science rocks.

Until next time...

Good Luck and Good Job Hunting!!!!!

 

Celebrate National DNA Day Tomorrow!

National DNA Day is a unique day when students, teachers and the public can learn more about genetics and genomics! The day commemorates the completion of the Human Genome Project in April 2003, and the discovery of DNA's double helix by Watson, Crick and Rosalind Franklin.

National DNA Day is usually observed on April 25 (it was created by the US Congress seven years ago), but this year the National Human Genome Research Institute (NHGRI) will hold most of its activities on Friday, April 24 to accommodate classroom schedules. Building upon the popularity of the online chatroom and ambassador programs, NHGRI and its DNA Day partners this year have expanded their outreach efforts even further by creating National DNA Day social networking pages on Facebook and Twitter.

National DNA Day is much more than a time to honor historical achievements. It's a day filled with opportunities for students, teachers and the public to learn how the exciting field of genome research affects our lives. NHGRI researchers, called DNA Day Ambassadors, are visiting dozens of high schools throughout the nation during April to give presentations and field questions from students. This year, NHGRI is particularly focusing on the southwest region of the United States, sending DNA Day ambassadors to high schools in Utah, Colorado, Arizona, New Mexico and Texas.

No matter where they live, students and teachers can participate in National DNA Day through a live, moderated online chat with NHGRI researchers, which will be open for questions Friday, April 24, from 8 a.m. to 6 p.m. Eastern. NHGRI experts will be available to answer questions on a wide range of topics, including basic science, clinical research, genomics careers and the ethical, legal and social implications of genome research. For those unable to participate in the live event, a transcript of the chat will be available on the DNA Day Web site at National DNA Day Online Chatroom.

You can also participate online on Facebook and @dnaday on Twitter

Happy Birthday DNA!

 

Goodbye "DNA"

It’s official!  Roche has secured more than 96 percent of shares in Genentech Inc, completing its $46.8 billion buyout of the U.S. biotech group. It now holds some 93 percent of outstanding Genentech shares, a further 3 percent are guaranteed to be delivered within the next three business days and it will integrate the U.S. biotech group as soon as possible.

Soon after Roche completed the transaction on Thursday, the company announced that Genentech's common stock would no longer be traded on the New York Stock Exchange.

Genentech, founded in 1976, was one of the first and most successful biotechnology companies in the US. After lagging behind rival Amgen for most of the 1990s, Genentech eclipsed Amgen in the early 2000s on the strength of its oncology franchise (Herceptin and Avastin) and its deep drug development pipeline.

Its acquisition by Roche truly signals the end of an era in history of the American biotechnology industry.

Until next time...

Good Luck and Good Cloning! 

SocialTwist Tell-a-Friend

Roche Takeover of Genentech Likely

Late last week, Roche raised the price of its hostile offer to buy out Genentech to $93 a share, from $86.50. While the Genentech board advised its shareholders that the company is worth $112 per share, many financial analysts believe that the $93 per share offer may entice institutional investors to “pull the trigger” on the deal. Roche also extended its offer to shareholders by a week, until March 20. Roche already owns over 65 percent of Genentech’s outstanding shares.

Roche has indicated that if fewer than half the minority shares were tendered, it would not buy any of the shares tendered by Genentech shareholders. The new offer is likely to bring in more than half the minority shares, which would raise Roche’s ownership to at least 78 percent. About 71 percent of 131 Genentech stockholders who responded to a survey by Deutsche Bank on Friday said they would tender at least some of their shares at $93, and of those, half said they would tender virtually all. It is not clear what will happen if Roche is unable to purchase 100% of Genentech's shares.

Roche is motivated to close the deal as quickly as possible before results are released next month from a clinical trial of Avastin, one of Genentech’s top-selling cancer drugs. That trial, testing Avastin as a treatment for colon cancer after surgical removal of the tumore, could open a huge new market for the drug, which is now approved to treat cancer only at a later stage. Positive results from the trial may push Genentech’s stock price to over $100 per share—something that Roche desperately doesn’t want to happen.

If Roche is successful in its takeover bid, it  will likely to result in massive layoffs at Roche’s Nutley, NJ headquarters. Previously, Roche announced that it would move its US headquarters from Nutley to the Bay area if it acquires Genentech. Not good news for the state of New Jersey which is still reeling from the Pfizer-Wyeth takeover announced six weeks ago and the Merck-Schering Plough merger mentioned earlier today.

Until next time...

Good Luck and Good Job Hunting!!!!!!!!

SocialTwist Tell-a-Friend

 

The Top 30 Technologies that Changed the World

A panel of eight judges at the Wharton School of Business at the University of Pennsylvania was asked to identify the top 20 life-altering technologies that were developed over the last 30 years. The survey was sponsored by Knowledge@ Wharton, U Penn’s business publication and the PBS’s “Nightly Business Report.” 

Not surprisingly, the Internet was voted the top innovation followed by computers, mobile phones and e-mail. Interestingly, DNA sequencing and testing was listed as number 5—one of five technologies from the life sciences and medical sectors—the others being MRI, laparoscopy, genetically-modified plants, biofuels and anti-retroviral (HIV) drugs. Finally, Internet social networking, a recent innovation, made a surprise appearance on the list at number 20!. The entire list is as follows:

  1. Internet, broadband, WWW (browser and html)
  2. PC/laptop computers
  3. Mobile phones
  4. E-mail
  5. DNA testing and sequencing/Human genome mapping
  6. Magnetic Resonance Imaging (MRI)
  7. Microprocessors
  8. Fiber optics
  9. Office software (spreadsheets, word processors)
  10. Non-invasive laser/robotic surgery (laparoscopy)
  11. Open source software and services (e.g., Linux, Wikipedia)
  12. Light emitting diodes
  13. Liquid crystal display (LCD)
  14. GPS systems
  15. Online shopping/ecommerce/auctions (e.g., eBay)
  16. Media file compression (jpeg, mpeg, mp3)
  17. Microfinance
  18. Photovoltaic Solar Energy
  19. Large scale wind turbines
  20. Social networking via the Internet
  21. Graphic user interface (GUI)
  22. Digital photography/videography
  23. RFID and applications (e.g., EZ Pass)
  24. Genetically modified plants
  25. Bio fuels
  26. Bar codes and scanners
  27. ATMs
  28. Stents
  29. SRAM flash memory
  30. Anti retroviral treatment for AIDS

If your favorite technology wasn’t listed in the Top 30, please let me know and we can add it to the list!

Until next time...

Good Luck and Good Job Hunting (try social networks)!!!!!!!

  

SocialTwist Tell-a-Friend

Home Brewing DNA

Have you ever felt like mixing up a few batches of DNA in your  spare time? Well, for those of you who sometimes get the urge I found an easy-to-use recipe to make your own custom designed DNA sequences. Of course I was joking about doing it at home but if you happen to be at the University of Wisconsin-Madison Biotechnology Center you can give it a whirl.

Of course, the ability to build DNA sequences nucleotide-by-nucleotide has been available for over a decade or more.  That said, the relatively simple system devised by scientists at the UW Biotechnology Center allows even the neophyte molecular biologist to do it successfully.

Until next time…

Good Luck and Good Genetic Engineering!!!!!!

Invitrogen to Acquire Applied Biosystems

The consolidation trend in the US life sciences industry continues. Carlsbad, CA-based Invitrogen, a provider of cells, molecular and biochemical probes and reagents used in life sciences research,announced on Thursday that it will acquire (merge) with automated DNA sequencer manufacturer Applied Biosystems (ABS).  Invitrogen will pay $6.7 billion in cash and stock to buy ABS which is an independent unit of Applera Corporation.

As most of you know, ABS supplied hundreds of automated DNA sequencing machines ($300,000 per machine) that were used to sequence the human genome. The advent of automated DNA sequencers in the mid to late 1990s helped (along with Craig Venter) to speed up efforts to complete the Human Genome project which officially began in 1990. The first draft of the human genome was published in 2001. Unfortunately for ABS, it was unable to refocus and adjust to changing business conditions after the government-sponsored human genome project ended in the early 2000s.  Attempts to reinvent the company included moving into commercial businesses like selling equipment to test food for pathogens or DNA from crime scenes.

The deal, if approved by regulators, would create a giant supplier of machines and materials used by academic and pharmaceutical industry research laboratories, with about $3.5 billion in annual sales. Although the deal makes sense from a business perspective, it is likely that there will be a “reallocation of corporate resources” once the merger is approved by European and US regulators.

Until next time….

Good Luck and Good Job Hunting (try Carlsbad, it is a great place)!!!!!!!!

The Demise of RNAi?

There is mounting evidence that RNAi, once hailed as a panacea for the pharmaceutical and biotechnology industries, may not be all that it was claimed to be. Yes, there are several new RNAi drug candidates in late stage clinical development but it isn’t clear, at this point, whether any of these products will ever make it to market. Companies like Allergan, Alnylam, Opko Health and Merck, which recently bought the RNAi company Sirna Therapeutics for $1.1 billion, have invested hundreds of millions of dollars and literally “bet the farm” on RNAi therapeutics.

The use of DNA and RNA as therapeutics is not a new or novel idea. Isis Pharmaceuticals, a pioneer and champion of oligonucleotide therapeutics, has only be able to bring a single, oligonucleotide-based product to market in the past 20 years. Ask any Isis executive and they will tell you that turning DNA or RNA into drugs is a challenging process that is fraught with many difficulties. Most notably, there are bioavailability, delivery and target specificity hurdles that most be over come before the utility of these drugs as therapeutic agents can be realized. That said the attractiveness of these molecules as therapeutics (and perhaps their real danger) is the simplicity and elegance of their mechanism(s) of action. Most scientists tend to “fall in love” with elegant and parsimonious solutions to complex processes—why would we not, they are type of discoveries that we all train and live for! And, as many of us know, when people “fall in love”, there is a tendency to overlook or not notice warning signs that things may not be as they seem.

The scientific community fell quickly and deeply in love with RNAi soon after the first papers appeared touting its benefits and possible therapeutic applications. Scientists were so convinced and confident about RNAi that they induced the financial community to invest billions of dollars into the emerging technology. The love and affection for RNAi reached its pinnacle in 2006 when two scientists, who played a crucial role in discovering its mechanism of action, won the Nobel Prize. Since then, the harsh realities of RNAi drug development have begun to be realized by companies that invested in the technology.

I have been around long enough to understand that there are fads in science. In the mid 1990s it was combinatorial chemistry, in the late 1990s it was genomics, proteomics and computational chemistry and in the 2000s it is RNAi. Don’t get me wrong–all of these technologies have helped to advance science and  provide researchers with sophisticated tools that have helped to expedite the drug discovery and development process. That said, none of these technologies, by themselves, yielded the plethora of new medications or therapeutics that their advocates promised. Industry veterans know that there are no easy solutions or panaceas in drug discovery and development. The process is inherently time-intensive, painstaking and tedious. And, despite what we scientists want to believe in our “heart of hearts,” there are no guarantees that simplicity and elegance will translate into safe and effective medications.

Until next time….

Good Luck and Good Job Hunting!!!!!!!!!!

A New DNA-Based Diagnostic Test to Predict Prostate Cancer

Sometimes things just seem to occur randomly or by cosmic convergence. Yesterday, my good friend Pete learned that he had prostate cancer. His prostate specific antigen (PSA) levels were slightly elevated over the past few years (they were in a gray zone that made a definitive diagnosis difficult without doing a biopsy). After being urged by his wife and urologist, he had the biopsy performed and, unfortunately, a diagnosis of prostate cancer was made. Hopefully, his cancer is localized to the prostate and will be easily treated via conventional therapies. As many of you may know, prostate cancer is easily treat and the cure rates high if it is detected early.

The use of PSA levels to diagnosis prostate cancer is notoriously unreliable and inaccurate.Today, a group of Swedish scientists announced that they developed a DNA-based test that showed that men carrying a combination of known risk genes run a four to five time higher risk of developing prostate cancer. They envision that this test could be used in tandem with PSA monitoring to more accurately diagnose prostate cancer. I hope that they are right!

Unfortunately, the new test wasn't developed in time to help Pete; but perhaps it can be used in the future to more accurately assess the risk and diagnose prostate cancer quickly so that treatment begins as soon as possible!

Until next time…

Good Luck and Good Job Hunting!!!!!!